NCT02999633 - Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

November 14, 2017

Study Completion Date

November 14, 2017

Conditions

T-cell Type Acute Leukemia-PrecursorT-lymphoblastic Lymphoma/Leukaemia

Interventions

DRUG

Isatuximab SAR650984

Pharmaceutical form:solution Route of administration: intravenous

DRUG

dexamethasone

Pharmaceutical form:pills Route of administration: oral

DRUG

dexamethasone

Pharmaceutical form:solution Route of administration: intravenous

DRUG

acetaminophen

Pharmaceutical form:pills Route of administration: oral

DRUG

ranitidine

Pharmaceutical form:solution Route of administration: intravenous

DRUG

diphenhydramine

Pharmaceutical form:solution Route of administration: intravenous

Trial Locations (17)

1083

Investigational Site Number 3480001, Budapest

1097

Investigational Site Number 3480003, Budapest

4032

Investigational Site Number 3480002, Debrecen

24127

Investigational Site Number 3800001, Bergamo

25123

Investigational Site Number 3800004, Brescia

30342

Investigational Site Number 8400002, Atlanta

33600

Investigational Site Number 2500004, Pessac

44093

Investigational Site Number 2500005, Nantes

69310

Investigational Site Number 2500002, Pierre-Bénite

75475

Investigational Site Number 2500001, Paris

77030

Investigational Site Number 8400001, Houston

117198

Investigational Site Number 6430003, Moscow

125167

Investigational Site Number 6430004, Moscow

129301

Investigational Site Number 6430001, Moscow

07601

Investigational Site Number 8400003, Hackensack

00029

Investigational Site Number 2460001, Helsinki

08661

Investigational Site Number 4400001, Vilnius